NASDAQ:FLNA Cassava Sciences (FLNA) Stock Price, News & Analysis $1.49 0.00 (0.00%) As of 06/1/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Cassava Sciences Stock (NASDAQ:FLNA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cassava Sciences alerts:Sign Up Key Stats Today's Range$1.49▼$1.6050-Day Range$1.18▼$2.3852-Week Range$1.16▼$4.98Volume579,050 shsAverage Volume396,508 shsMarket Capitalization$71.98 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingHold Company Overview Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapies and diagnostics for Alzheimer’s disease and related neurodegenerative disorders. Headquartered in Austin, Texas, the company was originally founded as Pain Therapeutics in 1998 and rebranded to Cassava Sciences in 2017. Cassava’s research program centers on small molecules designed to address underlying mechanisms of neurodegeneration rather than solely targeting amyloid plaques or tau tangles. The company’s lead drug candidate, simufilam (formerly PTI-125), is a proprietary small molecule that aims to restore normal shape and function to the scaffolding protein filamin A, which has been implicated in impaired neuronal signaling and inflammation in Alzheimer’s patients. Simufilam is being evaluated in Phase 2b and Phase 3 clinical trials, with studies conducted across multiple sites in the United States and Australia. Cassava also maintains a pipeline of diagnostics, including exploratory blood-based biomarkers intended to detect pathogenic hallmarks of Alzheimer’s disease at earlier stages. Cassava Sciences is led by President and Chief Executive Officer Remi Barbier, who has guided the company’s strategic transition from pain management to neurodegenerative research. The executive team comprises professionals with backgrounds in neuroscience, clinical development, and regulatory affairs. Cassava’s board includes members with extensive experience in the biotechnology and pharmaceutical industries, supporting the company’s efforts to advance its pipeline and engage with regulatory authorities. With a mission to transform the treatment and diagnosis of Alzheimer’s disease, Cassava Sciences collaborates with academic institutions and contract research organizations to conduct its clinical studies. While the company’s primary activities are centered in North America and Australia, it seeks to establish partnerships and expand its research footprint globally as it progresses its therapeutic and diagnostic programs toward regulatory approval.AI Generated. May Contain Errors. Read More Cassava Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreFLNA MarketRank™: Cassava Sciences scored higher than 41% of companies evaluated by MarketBeat, and ranked 693rd out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingCassava Sciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialCassava Sciences has a consensus price target of $5.00, representing about 235.6% upside from its current price of $1.49.Amount of Analyst CoverageCassava Sciences has only been the subject of 2 research reports in the past 90 days.Read more about Cassava Sciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Cassava Sciences is -0.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cassava Sciences is -0.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCassava Sciences has a P/B Ratio of 0.97. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.51% of the float of Cassava Sciences has been sold short.Short Interest Ratio / Days to CoverCassava Sciences has a short interest ratio ("days to cover") of 14.67, which indicates bearish sentiment.Change versus previous monthShort interest in Cassava Sciences has recently decreased by 2.29%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCassava Sciences does not currently pay a dividend.Dividend GrowthCassava Sciences does not have a long track record of dividend growth. News and Social Media3.0 / 5News Sentiment0.78 News SentimentCassava Sciences has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Cassava Sciences this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for FLNA on MarketBeat in the last 30 days. This is a decrease of -88% compared to the previous 30 days.MarketBeat Follows5 people have added Cassava Sciences to their MarketBeat watchlist in the last 30 days. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cassava Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders4.60% of the stock of Cassava Sciences is held by insiders.Percentage Held by Institutions38.05% of the stock of Cassava Sciences is held by institutions.Read more about Cassava Sciences' insider trading history. Receive FLNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cassava Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FLNA Stock News HeadlinesData I/O And 2 Other Promising Penny Stocks To WatchMay 29, 2026 | finance.yahoo.comFilana Therapeutics Reports Q1 2026 Financial Results and Business UpdateMay 7, 2026 | finance.yahoo.comA gold storm is coming – are you ready?The U.S. Treasury Secretary is betting big on gold - and the world's most successful investors are following suit ahead of what could be a massive market shift. But they're not buying bullion or coins. They're loading up on a niche asset with far more upside potential - and the details are available right now.June 2 at 1:00 AM | Traders Agency (Ad)Filana Therapeutics Reports Q1 2026 Financial Results and Business UpdateMay 7, 2026 | globenewswire.comFilana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIIIMay 5, 2026 | finance.yahoo.comFilana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIIIMay 5, 2026 | globenewswire.comFilana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial ResultsMarch 12, 2026 | finance.yahoo.comCassava Sciences to rebrand to Filana TherapeuticsMarch 10, 2026 | seekingalpha.comSee More Headlines FLNA Stock Analysis - Frequently Asked Questions How have FLNA shares performed this year? Cassava Sciences' stock was trading at $1.98 at the start of the year. Since then, FLNA stock has decreased by 24.7% and is now trading at $1.49. How were Cassava Sciences' earnings last quarter? Cassava Sciences, Inc. (NASDAQ:FLNA) announced its quarterly earnings data on Thursday, May, 7th. The company reported ($0.21) EPS for the quarter. When did Cassava Sciences' stock split? Shares of Cassava Sciences split before market open on Thursday, December 21st 2023.The 14-10 split was announced on Thursday, December 21st 2023. The newly created shares were issued to shareholders after the market closes on Thursday, December 21st 2023. An investor that had 100 shares of stock prior to the split would have 140 shares after the split. How do I buy shares of Cassava Sciences? Shares of FLNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cassava Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cassava Sciences investors own include Waste Connections (WCN), Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings5/07/2026Today6/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 FLNA's financial health is in the Red zone, according to TradeSmith. FLNA has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:FLNA Previous SymbolNASDAQ:SAVA CIK1069530 Webwww.filanatx.com Phone512-501-2444Fax512-501-0414Employees20Year Founded1998Price Target and Rating Average Price Target for Cassava Sciences$5.00 High Price Target$5.00 Low Price Target$5.00 Potential Upside/Downside+235.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($1.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$90.97 million Net MarginsN/A Pretax MarginN/A Return on Equity-53.90% Return on Assets-34.20% Debt Debt-to-Equity RatioN/A Current Ratio2.19 Quick Ratio2.19 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.54 per share Price / Book0.97Miscellaneous Outstanding Shares48,310,000Free Float46,086,000Market Cap$71.98 million OptionableOptionable Beta-0.72 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:FLNA) was last updated on 6/2/2026 by MarketBeat.com Staff. From Our PartnersThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredPresident Trump just sparked a stock market MELT UPThe real reason Musk, Huang, Cook, and Fink just flew to Beijing Last week, the CEOs of Nvidia, Apple, Spac...Stansberry Research | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredThe roadshow starts Monday. This stock isn't ready.The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...Behind the Markets | SponsoredI stumbled into this at 3 PMEvery trading day, $55 billion floods the market in the final hour between 3 and 4 PM Eastern. One trader noti...Trade To Close | SponsoredSecret behind near perfectly timed stock trades…?After 20 years of professional trading, Ross Givens says this is the single most lucrative market strategy he ...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cassava Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cassava Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
